This study is a double-blind randomized controlled superiority trial aiming at providing
evidence on the efficacy and safety of co-administered moxidectin and albendazole versus
albendazole monotherapy (standard of care) against whipworm (T. trichiura) infections in
adolescents and adults (12-60 years) in Côte d'Ivoire. One arm of patients will be treated
with albendazole-ivermectin.
As measure of efficacy of the treatment the cure rate (percentage of egg-positive subjects at
baseline who become egg-negative after treatment) will be determined 14-21 days
post-treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Jennifer Keiser
Collaborator:
Centre Suisse de Recherches Scientifiques en Cote d'Ivoire